Incidence and clinical profile of venous thromboembolism in hospitalized COVID-19 patients from Madrid region. Issue 203 (July 2021)

• Record Type: Journal Article
• Authors: Arribalzaga, Karmele; Martínez-Alfonzo, Inés; Díaz-Aizpún, Carola; Gutiérrez-Jomarrón, Isabel; Rodríguez, Mario; Castro Quismondo, Nerea; Pérez-Fernández, Elia; Velasco-Rodríguez, Diego; Gómez, Elvira; Fernández, Begoña; Vilches, Alba; Martín-Herrero, Sara; Castilla, Lucía; Blanco, María Jesús; Gutiérrez, María del Mar; Rivas, Isabel; Pascual, Cristina; Rosado, Belén; Sola, Elena; Vidal-Laso, Rosa; Asenjo, Susana; Mora Casado, María Asunción; Benito-Parra, Laurentino; Carmona, Itziar; Marín, Karen; Acedo, Natalia; García-León, Natalia; Marcheco, Alexis; Guillén, Carolina; Fernández, Cristina; Rodríguez, Ramón; Pardo, Laura; Silva, Pablo; Montero, Laura; Meijón, Mar; Massó, Pilar; Llamas-Sillero, Pilar;
• Is Part Of: Thrombosis research. Issue 203(2021)
• Page Start: 93
• Page End: 100
• Publication Date: 2021-07
• Subjects: COVID19 -- Incidence -- Multicenter study -- Pulmonary embolism -- Venous thromboembolism -- Thromboprophylaxis; Thrombosis -- Periodicals; 616.135
• DOI: 10.1016/j.thromres.2021.05.001
• Languages: English
• ISSNs: 0049-3848

Abstract

Abstract: Background: COVID-19 related in-hospital venous thromboembolism (VTE) incidence is high but data reported vary significantly. Some studies show that up to half of the events are diagnosed early after admission. Objectives: To study symptomatic VTE incidence in acute COVID-19 hospitalized patients and to describe timing of VTE diagnosis. Methods: Multicenter cohort of 5966 patients hospitalized with acute COVID-19. Multicenter Registry of 844 hospitalized patients with acute COVID-19 and associated acute VTE. Results: By the time of cohort data collection, 68 patients (1.14%) were still hospitalized, 19.8% had died, and 5.4% required ICU. During a median follow-up of 6 days (IQR, 4–12), 183 patients (3.07%; 95% CI, 2.64–3.55) presented a symptomatic VTE event. The cumulative incidences of VTE at 7, 14 and 21 days in wards [2.3% (95% CI, 1.9–2.7), 3.6% (95% CI, 3.0–4.3), and 4.3% (95% CI, 3.5–5.1)] were similar to the ones reported in ICU [2.2% (95% CI, 1.0–4.4), 2.9% (95% CI, 1.5–5.3), and 4.1% (95% CI, 2.2–6.8)], but at 30 and 60 days were higher in ICU [6.9% (95% CI, 4.2–10.5), and 12.8% (95% CI, 8.1–18.5)] than in wards. Eighty-eight VTE events (48%) were diagnosed early, within 48 h of admission. VTE was not associated with death (HR, 0.79; 95% CI, 0.55–1.12). Conclusions: Incidence of symptomatic VTE in our COVID-19 cohort is consistent with that of other real-life studies recently published. Early VTE events are, along with COVID-19, the reason for admission rather than an in-hospital complication. Highlights: Data on venous thrombosis (VTE) incidence in hospitalized COVID-19 patients vary significantly. Large real-life studies show lower VTE incidences than small studies. In Intensive Care Unit, symptomatic VTE incidence in COVID-19 vs. non-COVID-19 patients may be similar. In ICU, symptomatic VTE incidence in COVID-19 vs. non-COVID-19 patients may be similar. Half of VTE events are diagnosed within first 48 h.